This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| common variable immunodeficiency | |
|---|---|
| Name | Common variable immunodeficiency |
| Synonym | CVID |
| Specialty | Immunology |
| Symptoms | Recurrent infections, hypogammaglobulinemia, autoimmunity |
| Complications | Bronchiectasis, lymphoma, enteropathy |
| Onset | Childhood to adulthood |
| Duration | Chronic |
| Causes | Heterogeneous genetic and environmental factors |
| Diagnosis | Serum immunoglobulins, vaccine response, B cell phenotyping |
| Treatment | Immunoglobulin replacement, antimicrobials, immunomodulation |
common variable immunodeficiency
Common variable immunodeficiency is a heterogeneous primary immunodeficiency characterized by low immunoglobulin levels and impaired antibody responses, leading to recurrent infections, autoimmunity, and increased risk of lymphoproliferative disorders. It affects children and adults and is managed by immunoglobulin replacement, infection control, and monitoring for complications.
Common variable immunodeficiency presents with hypogammaglobulinemia, especially reduced IgG and IgA, and impaired specific antibody production, with variable B cell abnormalities described in clinical series from major centers such as Mayo Clinic, Johns Hopkins Hospital, Great Ormond Street Hospital, Karolinska Institute, and Imperial College London. Epidemiologic and registry data have been collated by organizations including the European Society for Immunodeficiencies, the Immune Deficiency Foundation, and national surveillance programs in United Kingdom, United States, Sweden, Japan, and Australia. Diagnostic criteria and management guidelines have been developed by panels convened at meetings in venues like World Health Organization affiliated conferences and symposia hosted by American Academy of Allergy, Asthma & Immunology, European Respiratory Society, and academic departments at Harvard Medical School and Stanford University.
Patients commonly present with recurrent bacterial sinopulmonary infections such as sinusitis and pneumonia observed in series from Centers for Disease Control and Prevention, Royal College of Physicians, and tertiary clinics at Massachusetts General Hospital and Mayo Clinic. Other presentations include chronic diarrheal illness and malabsorption reported by gastroenterology services at Cleveland Clinic and Mount Sinai Hospital, autoimmune cytopenias documented in cohorts from University College London and Johns Hopkins Hospital, and granulomatous disease described in case series from University of Oxford and University of Toronto. Complications such as bronchiectasis are managed in multidisciplinary clinics involving specialists from American Thoracic Society, European Lung Foundation, and centers like Royal Brompton Hospital. Lymphoma and other malignancies have been reported by oncology services at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and national cancer registries in France, Germany, and Italy.
CVID is genetically heterogeneous, with pathogenic variants identified in genes such as TNFRSF13B (encoding TACI), ICOS, CD19, CD20, LRBA, CTLA4, and PIK3CD in subsets of patients described by genetics groups at Broad Institute, Genomics England, Wellcome Sanger Institute, and university labs at University of Cambridge, Yale University, and University of California, San Francisco. Immunopathology involves impaired B cell differentiation and reduced memory B cells, findings replicated in immunology laboratories at La Jolla Institute for Immunology and National Institutes of Health. Dysregulated T cell help, aberrant regulatory pathways involving CTLA4 and LRBA, and defects in signaling pathways such as PI3Kδ (studied at Dana–Farber Cancer Institute and Fred Hutchinson Cancer Center) contribute to autoimmunity and lymphoproliferation. Environmental triggers and modifier loci reported in population studies from Icelandic Health Authorities, Danish National Biobank, and UK Biobank suggest multifactorial etiology.
Diagnostic evaluation follows consensus statements from panels including specialists from European Society for Immunodeficiencies, American Academy of Allergy, Asthma & Immunology, and academic centers such as Johns Hopkins Hospital and Mayo Clinic. Key tests include quantitative serum immunoglobulins measured in clinical labs at Quest Diagnostics and Mayo Clinic Laboratories, assessment of vaccine-specific antibody responses used by public health agencies like Public Health England and Centers for Disease Control and Prevention, and flow cytometric B cell phenotyping performed at university hospitals including Karolinska University Hospital and Hospital for Sick Children (Toronto). Genetic testing is provided by reference laboratories such as Invitae, GeneDx, and research programs at Broad Institute and Genomics England to identify monogenic causes in subsets of patients.
Primary treatment is immunoglobulin replacement therapy—intravenous immunoglobulin or subcutaneous immunoglobulin—administered following protocols developed at centers like Mayo Clinic, Johns Hopkins Hospital, and infusion programs coordinated by hospitals such as Cleveland Clinic and Mount Sinai Hospital. Antimicrobial prophylaxis and acute antimicrobial therapy follow guidelines from Infectious Diseases Society of America and European Society for Clinical Microbiology and Infectious Diseases; pulmonology teams at Royal Brompton Hospital and National Jewish Health manage bronchiectasis. Autoimmune complications are treated with immunosuppressive agents informed by hematology services at Memorial Sloan Kettering Cancer Center and rheumatology clinics at Hospital for Special Surgery and University College London Hospitals. Targeted therapies, including abatacept for CTLA4 deficiency and PI3Kδ inhibitors for activated PI3Kδ syndrome, have been studied at Dana–Farber Cancer Institute and pharmaceutical trials run in collaboration with companies such as Roche, Novartis, and GSK.
Long-term outcomes vary; cohort studies from Mayo Clinic, Johns Hopkins Hospital, Karolinska Institute, and national registries in Norway and Netherlands report morbidity from chronic lung disease, enteropathy, and hematologic malignancies. Survival is influenced by age at diagnosis, severity of infections, and control of complications; cancer risk including non-Hodgkin lymphoma has been documented by oncology registries at SEER and cancer centers like MD Anderson. Multidisciplinary follow-up in clinics affiliated with European Reference Network centers and comprehensive care programs at institutions such as Great Ormond Street Hospital improves outcomes.
Prevalence estimates derive from population studies in United Kingdom, United States, Sweden, Japan, and Australia compiled by public health agencies and advocacy groups like the Immune Deficiency Foundation and European Society for Immunodeficiencies. Reported prevalence ranges from 1:25,000 to 1:100,000, with diagnostic delays described in analyses by National Health Service audits, CDC surveillance, and research consortia including ESID registry and national immunodeficiency registries in France and Germany. Sex distribution and age at presentation vary across cohorts from tertiary centers such as Mayo Clinic and Johns Hopkins Hospital.
Recognition of hypogammaglobulinemic syndromes precedes modern immunogenetics and was described in early clinical reports in hospitals like Massachusetts General Hospital and Guy's Hospital; landmark reviews and criteria were advanced by investigators at NIH and European groups including ESID and WHO consultative meetings. Current research priorities at institutions including Broad Institute, Wellcome Trust Sanger Institute, Harvard Medical School, and Stanford University focus on genotype–phenotype correlations, targeted therapies (studied in trials sponsored by NIH and pharmaceutical partners AstraZeneca and Pfizer), and improving registries such as ESID registry and USIDNET. Emerging avenues include gene editing research at CRISPR Therapeutics collaborations with academic centers, microbiome studies involving teams at Weizmann Institute of Science, and precision medicine initiatives at All of Us Research Program and Genomics England.
Category:Primary immunodeficiency diseases